Congress Aims

Who will Dominate Healthcare & Medicine
  • Next generation business models amid value-based compensation
  • Customers versus patient engagement
  • How will the payer, provider role change
Data Sciences
  • AI a hyped buzzword
  • Machine/Deep Learning
  • Topological data analysis
  • Validating “black box” analytics
  • Garbage in – garbage out
Clinical research & development
  • Next generation clinical trials, N-of-1, longitudinal trials as an emerging paradigm
  • “Virtual” or remote clinical trials, sensors
  • Real World studies
  • Rare diseases as role models for large indications; how to 
  • Choose the best end point study that provides answers and that has a high probability of achievement
  • Design studies that provide high quality data and can be used for decision making 
  • Include criteria that enable fast recruitment of patients;  Choose design elements and inclusion/exclusion criteria that increase the probability of success for the study
  • Ensure the best retention rate
Regulatory Process, Data Safety & Security
  • Machine/Deep Learning, next generation “biomarkers”
  • Help the regulatories develop a fast track approval for clinical studies on all levels (EMA/FDA, Country level, Institute level)
  • Encourage off label to label studies 
  • Enable collaboration between regulatories, payers, industry and academia, to ensure high probability of successful drug marketing
  • Implementing GDPR
  • Design RCT’s using electronic charts
  • Use electronic chart to study real world efficacy and safety of drugs and device
Financing Disruption
  • Who should found necessary moonshots 
  • VCs, impact investors, payers and government roles